HealthLinx Inks Deals for Prostate Cancer Biomarkers, Ovarian Cancer Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – HealthLinx separately announced this month a collaboration with the Garvan Institute of Medical Research to assess HealthLinx's IP for prostate cancer, and the appointment of CPC Clinical Research to aid it in obtaining approval from US regulators for its ovarian cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."